Prolonged lymphocytosis during ibrutinib therapy is

Prolonged lymphocytosis during ibrutinib therapy is
associated with distinct molecular characteristics and
does not indicate a suboptimal response to therapy
by Jennifer A. Woyach, Kelly Smucker, Lisa L. Smith, Arletta Lozanski, Yiming
Zhong, Amy S. Ruppert, David Lucas, Katie Williams, Weiqiang Zhao, Laura
Rassenti, Emanuela Ghia, Thomas J. Kipps, Rose Mantel, Jeffrey Jones, Joseph
Flynn, Kami Maddocks, Susan O’Brien, Richard R. Furman, Danelle F. James, Fong
Clow, Gerard Lozanski, Amy J. Johnson, and John C. Byrd
Blood
Volume 123(12):1810-1817
March 20, 2014
©2014 by American Society of Hematology
Protein and gene expression of BCR signaling components in persistent lymphocytes compared
with baseline.
Woyach J A et al. Blood 2014;123:1810-1817
©2014 by American Society of Hematology
Nuclear and cytoplasmic localization of BTK, ERK, and AKT in persistent lymphocytes following
ibrutinib therapy and ability of persistent lymphocytes to stimulate.
Woyach J A et al. Blood 2014;123:1810-1817
©2014 by American Society of Hematology
Real-time PCR of BCR pathway–associated genes in persistent lymphocytes.
Woyach J A et al. Blood 2014;123:1810-1817
©2014 by American Society of Hematology
Persistent lymphocytes are not addicted to a single signaling pathway.
Woyach J A et al. Blood 2014;123:1810-1817
©2014 by American Society of Hematology
PFS of patients with persistent lymphocytosis is not inferior to those achieving complete or PR
by 12 months.
Woyach J A et al. Blood 2014;123:1810-1817
©2014 by American Society of Hematology